Overview

Ruxolitinib in the Treatment of Covid-19

Status:
Not yet recruiting

Trial end date:
2020-09-15

Target enrollment:

Participant gender:

Summary

The treatment of COVID-19 severe acute respiratory syndrome with ruxolitinib 5 mg orally every 12 hours during 14 days would stop the disproportionate inflammatory response, causing a reduction in the proportion of patients who show a progression and worsening of the severe acute respiratory syndrome.

Phase:

Phase 2

Details

Lead Sponsor:

Marcelo Iastrebner

Collaborator:

Novartis